Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Neuralstem: A Closer Look at Encouraging Phase 2 Results for NSI-566 Neural Stem Cells in Treating ALS (CUR, Buy, $2.36)

Observations about the Phase 2 Trial Results

I spent the weekend thinking about the data released in the phase 2 trial…
Read more…

Neuralstem: Initial Take on Top Line Results of Phase 2 ALS Trial of NSI-566 Neural Stem Cells (CUR, Buy, $3.08)

The topline data for the phase 2 trial of NSI-566 stem cells were released today. The initial stock reaction indicates…
Read more…

Neuralstem: When Will We See the Phase 2 Data for NSI-566 in ALS? (CUR, Buy, $3.75)

Management has guided that the phase 2 data on 15 patients treated in the phase 2 trial of NSI-566 neural…
Read more…

Neuralstem: Some Encouraging, But Very Early, Information on Chinese Ischemic Stroke Trial Using NSI-566 Stem Cells (CUR, Buy, $2.59)

Purpose of This Blog

I received this e-mail communication from a SmithOnStocks subscriber who has a good insight into the Chinese…
Read more…

Neuralstem: Investigators are Very Positive on NSI-566 Results in ALS (CUR, Buy, $3.27)

Investment Perspective

The key investigators for the treatment of ALS with Neuralstemís NSI-566 neural stem cells have been extremely positive in…
Read more…

Neuralstem: Previewing Upcoming Important Events and Some Thoughts on the StemCell Patent Infringement Lawsuit (CUR, $3.62 Buy, August 26, 2014)

Key Points

The phase 2 trial of NSI-566 in 15 ALS patients has completed enrollment (surgeries) and final topline data could…
Read more…

Neuralstem (CUR, Buy, $4.48) Publishing of Phase 1 Results in Annals of Neurology Causes Price Surge (Paid Subscribers Only)

Introduction

The final results of the phase 1 trial of Neuralstemís (CUR) NSI-566 spinal cord stem cells in the treatment of…
Read more…

Neuralstem: Sizing Up Potential Key Events of 2014 (CUR, $3.42)

Investment Thesis and Overview
Neuralstemís clinical trial programs and accompanying results for its two key drugs, the neural stem cell product…
Read more…

Neuralstem: Evidence Increasingly Suggests its Neural Stem Cells are Effective in ALS (CUR, $2.57)

Thoughts on the Stock Price
I have been recommending Neuralstem†(CUR) since my initiation report†of November 5, 2012 at a price of…
Read more…